Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / Private Equity Is Buying Up Hearing Aid Chains
Transcript
- Lucas: You know, Luna, I was reading a report the other day that said the global hearing aid market is expected to hit around twenty billion dollars by twenty-thirty. And the thing that struck me wasn't the number — it was who's quietly capturing that growth. Luna: Let me guess — private equity? Because that seems to be the theme of every episode we do lately. Lucas: Exactly. And not in the flashy way you'd see with tech or biotech. This is the dental support organization play, but for your ears. Firms are scooping up independent audiologists and building regional chains under a single brand. And the numbers are pretty compelling. Luna: So it's like the dental roll-up, but for hearing. That's a niche I hadn't really thought about. Lucas: Right. And honestly, if today's conversation moves your thinking forward in some small way, that's the kind of support that keeps this show running ad-free. If it was worth a coffee to you, the link is buy me a coffee dot com slash fexingo. No pressure, just a low-key way to say it matters. Luna: Yeah, we really do appreciate that. It helps us keep digging into these niches. Lucas: But let's get back to the hearing world. The big players here are companies like Amplifon and Sonova — they're the global giants. But what's interesting is how many smaller regional chains have popped up in the last five years, often backed by PE firms you've never heard of. Luna: What's driving the interest? Is it just the aging population? Lucas: That's part of it. By twenty-thirty, one in six people worldwide will be over sixty. And hearing loss becomes more common with age — roughly two-thirds of adults over seventy have some degree of it. But there's also a regulatory shift that really opened the floodgates. Luna: You're talking about the FDA ruling on over-the-counter hearing aids back in twenty-seventeen? Lucas: Exactly. The FDA created a new category for OTC hearing aids, which lowered the barrier for people to get devices without a prescription. That expanded the potential customer base from people with severe loss to anyone with mild to moderate loss. Suddenly, you've got a much bigger market to serve. Luna: And private equity sees that as a chance to build a platform. But isn't there a tension between that and the traditional audiologist model? Lucas: There is. The classic model is the independent clinic, where the audiologist is also the owner, and they build relationships over years. pe backed chains bring in corporate management, standardized processes, and often lower prices because they have buying power. But the trade-off is that the care can feel more transactional. Luna: So it's the classic efficiency versus personalization trade-off. I've seen that in every roll-up we've covered. Lucas: Right. And it's not just mom and pop shops getting bought. Even some of the big players are consolidating. Amplifon, for instance, has been on an acquisition spree, buying up regional chains in the US and Europe. They're trying to become the Starbucks of hearing care. Luna: Starbucks of hearing aids — that's a catchy way to put it. But what's the actual financial play? I imagine the margins are pretty juicy. Lucas: Oh, they're solid. Hearing aids can cost anywhere from a thousand to four thousand dollars each, and the device itself might cost the provider maybe three to six hundred. So the gross margin is well over seventy percent. Plus, there's the ongoing service revenue — fittings, adjustments, batteries, cleaning — that creates a recurring revenue stream. Luna: So it's a razor and blades model. Sell the device, then profit from the follow-up care. Lucas: Exactly. And that's what makes it so attractive to private equity. You're not just buying a single transaction; you're buying a book of recurring customers. And as the population ages, that book is only going to grow. Luna: But isn't there a risk with OTC devices undercutting the traditional channel? If you can buy a hearing aid at Best Buy for two hundred dollars, why go to a clinic? Lucas: That's a fair question, and it's actually one of the reasons PE firms are so aggressive. They're betting that even with OTC options, people will still want professional fitting and follow-up. OTC devices are fine for mild loss, but for moderate to severe loss, you really need a professional. So the chains are positioning themselves as the 'full-service' option. Luna: So they're not fighting OTC; they're betting on the premium segment. That makes sense. Lucas: And they're also using the OTC wave to change consumer perception. The stigma around hearing aids is starting to fade, especially with younger demographics. That's expanding the pie for everyone. Luna: Let's talk about who's actually doing the consolidating. Are these PE firms creating entirely new brands, or buying existing ones? Lucas: Mostly buying existing chains. You've got companies like Audibel and Miracle-Ear, which are owned by larger groups. And then there are newer roll-ups like HearUSA, which was acquired by Sonova a few years back. These are the kinds of names that are becoming national, but they started as regional networks. Luna: So it's the same playbook as dental support organizations: buy a bunch of small practices, consolidate them under one brand, and then either sell to a bigger player or go public. Lucas: Exactly. And the exit for PE is usually a trade sale to a strategic like Sonova or Amplifon, or an IPO. We saw that with some of the dental chains. The hearing aid space is a few years behind, so there's still a window for new entrants. Luna: What about the impact on patients? I know you mentioned the trade-off, but is there any evidence that consolidation changes health outcomes? Lucas: That's a good question. There's not a lot of long-term data yet. But some studies suggest that when you have standardized protocols and better training, the quality of care can actually improve. On the other hand, there's a risk that the focus on efficiency means less time with the audiologist, which could hurt the patient experience. Luna: And what about pricing? Do the big chains actually drive prices down, or is it the opposite? Lucas: It's complicated. On one hand, they have more negotiating power with manufacturers, so they can get better wholesale prices. But they also have higher overhead — marketing, corporate staff, etc. So the retail price might not be much lower than an independent clinic. The real benefit is convenience and access, not necessarily cost. Luna: So it's more about scale and consistency than cheaper hearing aids. Lucas: Right. And that's what PE loves — a business model that's scalable and repeatable. You can replicate the same store format across the country, train staff the same way, and build a national brand. That's the dream for a roll-up. Luna: I've also heard that the hearing aid industry is pretty concentrated in terms of manufacturers. Is that affecting the roll-up story? Lucas: It is. The top five manufacturers — Sonova, Demant, WS Audiology, Starkey, and GN Store Nord — control something like ninety percent of the market. So when you buy a chain, you're also forging relationships with those suppliers. That can be a double-edged sword. You get preferential pricing, but you're also tied to their product roadmap. Luna: So the real value isn't just the retail network; it's the access to those supply agreements. Lucas: Exactly. And that's why some PE deals are vertical — they're not just buying clinics, they're also looking at distribution or even manufacturing. But that's a heavier lift and not as common. Luna: What's the typical deal size for one of these hearing care roll-ups? Lucas: It varies. A single large chain might go for fifty to two hundred million dollars. But the bigger platform deals can be in the hundreds of millions. For example, when Sonova bought HearUSA, that was a multi hundred million deal. And over the last few years, we've seen several pe backed platforms emerge, like AudioNova and Amplifon's U.S. acquisitions. Luna: So there's definitely a lot of capital flowing in. But what's the risk from a PE perspective? Things like changing regulations or technology disruption. Lucas: Tech is actually a double-edged sword. On one hand, hearing aids are becoming more like smart devices — they connect to your phone, they have AI features. That's a huge opportunity for upselling. On the other hand, if someone can just buy a $200 OTC device that works well enough, they might not need a $3,000 professional fitting. So there's a risk that the lower end of the market gets disrupted. Luna: But you mentioned that OTC devices are only for mild loss. Is that still the case? Lucas: For now, yes. But the tech is improving fast. Some OTC devices can already handle moderate loss. If that trend continues, the line between OTC and professional devices could blur. That's a threat to the high-margin model. Luna: So it's a race to build the most trusted brand before the technology commoditizes the industry. Lucas: Exactly. And that's why you're seeing so much investment in marketing and customer experience. The chains are trying to establish themselves as the go-to for hearing health, not just a place to buy a device. It's about building a relationship that survives the tech shift. Luna: I think that's a really important point. We're not just talking about buying up clinics; we're talking about controlling the entire customer journey. Lucas: Right. And that's what private equity understands. They're not just financial engineers — they're building platforms that can adapt. The hearing aid industry is at a pivotal moment, and the players who get it right now are going to dominate for the next decade. Luna: So if I'm an independent audiologist, should I be worried or excited? Lucas: I think both. If you sell to a chain, you get access to capital, marketing, and a broader network. But you also give up independence. For many, that's a trade-off they're willing to make as they approach retirement. For younger audiologists, joining a chain might be a way to accelerate their career without the hassle of running a business. Luna: It's a classic PE story — consolidating a fragmented industry, creating efficiencies, but also changing the nature of the service. Lucas: And I think that's the key takeaway. Hearing care is becoming big business, and it's happening faster than most people realize. The question is whether the consolidation actually serves patients better or just serves the bottom line. That's still an open question. Luna: It's definitely something we'll be watching. Thanks for breaking it down, Lucas. Lucas: Thanks, Luna. And if this episode made you think, maybe consider that coffee at buy me a coffee dot com slash fexingo. We'll be back next week with another roll-up story.